Glycoproteomics-based cancer marker discovery adopting dual enrichment with Wisteria floribunda agglutinin for high specific glyco-diagnosis of cholangiocarcinoma

Atsushi Matsuda, Atsushi Kuno, Hideki Matsuzaki, Toru Kawamoto, Toshihide Shikanai, Yasuni Nakanuma, Masakazu Yamamoto, Nobuhiro Ohkohchi, Yuzuru Ikehara, Junichi Shoda, Jun Hirabayashi, Hisashi Narimatsu

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Cholangiocarcinoma (CC) is a lethal malignancy because it exhibits asymptomatic growth infiltrating the surrounding structures and therefore is usually detected at an advanced stage. The mainstay of treatment for CC is complete resection with negative surgical margins. Therefore, its diagnosis at a relatively early stage is demanded for performing relevant surgical resection. Since the definitive CC diagnosis depends on invasive methods such as biliary cytology and biopsy, a noninvasive assay with high diagnostic accuracy is keenly required. We therefore developed a CC marker with high specificity by the Wisteria floribunda agglutinin (WFA)-assisted glycoproteomics approach. WFA-positive glycoproteins were enriched by the direct dissection of the WFA-stained CC tissue region and following WFA-agarose column chromatography. Subsequent analysis by mass spectrometry identified 71 proteins as candidate markers. Screening of these candidates by gene expression profiling and immunohistochemistry resulted in the selection of L1 cell adhesion molecule (L1CAM) as the most specific CC marker. We confirmed the importance of WFA-positivity for L1CAM using both bile and serum of CC and benign bile duct disease patients. Specifically, WFA-positive L1CAM was enriched from serum by the WFA-assisted affinity capturing, with which CC was efficiently distinguished from benign. In the primary verification study using bile from CC patients (n. =. 29) and that of benign bile duct disease (n. =. 29), WFA-positive L1CAM distinguished CC with high specificity (sensitivity. =. 0.66, specificity. =. 0.93, overall accuracy. =. 0.79, area under the receiver operating curve [AUC]. =. 0.82). The combined use of the WFA-positive L1CAM assay with the high sensitive assay detecting WFA-positive sialylated mucin 1 sufficiently improved the diagnostic accuracy of CC (overall accuracy. =. 0.84, AUC. =. 0.93). This combination will possibly be a precise procedure for CC diagnosis compared with conventional diagnostic techniques. Biological significanceIn this study, we constructed the system for verification of the candidate molecules that exhibit disease specific glyco-alterations and discovered a useful CC marker by the glycoproteomics-assisted strategy for biomarker discovery. Based on the strategy, we previously found that WFA is the best probe to detect CC-specific glycosylation and WFA-positive sialyl MUC1 as a possible biomarker candidate. While the diagnostic specificity of WFA-positive sialyl MUC1 was not superb, we proposed a new biomarker candidate WFA-positive L1CAM with high specificity in bile and serum to complement the previous one. We proved that the novel combination assay of WFA-L1CAM and WFA-sialyl MUC1 selected based on our strategy has the possibility to become a reliable serological test. This study represents application of our strategy, which can be extrapolated to discovery of marker candidates for other diseases.

Original languageEnglish
Pages (from-to)1-11
Number of pages11
JournalJournal of Proteomics
Volume85
DOIs
Publication statusPublished - 2013 Jun 24
Externally publishedYes

Fingerprint

Cholangiocarcinoma
Neural Cell Adhesion Molecule L1
Neoplasms
Assays
Biomarkers
Bile Duct Diseases
Bile
wisteria lectin
Ducts
Area Under Curve
Serum
Cytology
Glycosylation
Dissection
Mucin-1
Agarose Chromatography
Column chromatography
Biopsy
Gene Expression Profiling
Serologic Tests

Keywords

  • Biomarker
  • Cholangiocarcinoma
  • Glycoprotein
  • L1CAM
  • Lectin

ASJC Scopus subject areas

  • Biochemistry
  • Biophysics

Cite this

Glycoproteomics-based cancer marker discovery adopting dual enrichment with Wisteria floribunda agglutinin for high specific glyco-diagnosis of cholangiocarcinoma. / Matsuda, Atsushi; Kuno, Atsushi; Matsuzaki, Hideki; Kawamoto, Toru; Shikanai, Toshihide; Nakanuma, Yasuni; Yamamoto, Masakazu; Ohkohchi, Nobuhiro; Ikehara, Yuzuru; Shoda, Junichi; Hirabayashi, Jun; Narimatsu, Hisashi.

In: Journal of Proteomics, Vol. 85, 24.06.2013, p. 1-11.

Research output: Contribution to journalArticle

Matsuda, A, Kuno, A, Matsuzaki, H, Kawamoto, T, Shikanai, T, Nakanuma, Y, Yamamoto, M, Ohkohchi, N, Ikehara, Y, Shoda, J, Hirabayashi, J & Narimatsu, H 2013, 'Glycoproteomics-based cancer marker discovery adopting dual enrichment with Wisteria floribunda agglutinin for high specific glyco-diagnosis of cholangiocarcinoma', Journal of Proteomics, vol. 85, pp. 1-11. https://doi.org/10.1016/j.jprot.2013.04.017
Matsuda, Atsushi ; Kuno, Atsushi ; Matsuzaki, Hideki ; Kawamoto, Toru ; Shikanai, Toshihide ; Nakanuma, Yasuni ; Yamamoto, Masakazu ; Ohkohchi, Nobuhiro ; Ikehara, Yuzuru ; Shoda, Junichi ; Hirabayashi, Jun ; Narimatsu, Hisashi. / Glycoproteomics-based cancer marker discovery adopting dual enrichment with Wisteria floribunda agglutinin for high specific glyco-diagnosis of cholangiocarcinoma. In: Journal of Proteomics. 2013 ; Vol. 85. pp. 1-11.
@article{541e4e3237a54cbb801a338dc7fd43e7,
title = "Glycoproteomics-based cancer marker discovery adopting dual enrichment with Wisteria floribunda agglutinin for high specific glyco-diagnosis of cholangiocarcinoma",
abstract = "Cholangiocarcinoma (CC) is a lethal malignancy because it exhibits asymptomatic growth infiltrating the surrounding structures and therefore is usually detected at an advanced stage. The mainstay of treatment for CC is complete resection with negative surgical margins. Therefore, its diagnosis at a relatively early stage is demanded for performing relevant surgical resection. Since the definitive CC diagnosis depends on invasive methods such as biliary cytology and biopsy, a noninvasive assay with high diagnostic accuracy is keenly required. We therefore developed a CC marker with high specificity by the Wisteria floribunda agglutinin (WFA)-assisted glycoproteomics approach. WFA-positive glycoproteins were enriched by the direct dissection of the WFA-stained CC tissue region and following WFA-agarose column chromatography. Subsequent analysis by mass spectrometry identified 71 proteins as candidate markers. Screening of these candidates by gene expression profiling and immunohistochemistry resulted in the selection of L1 cell adhesion molecule (L1CAM) as the most specific CC marker. We confirmed the importance of WFA-positivity for L1CAM using both bile and serum of CC and benign bile duct disease patients. Specifically, WFA-positive L1CAM was enriched from serum by the WFA-assisted affinity capturing, with which CC was efficiently distinguished from benign. In the primary verification study using bile from CC patients (n. =. 29) and that of benign bile duct disease (n. =. 29), WFA-positive L1CAM distinguished CC with high specificity (sensitivity. =. 0.66, specificity. =. 0.93, overall accuracy. =. 0.79, area under the receiver operating curve [AUC]. =. 0.82). The combined use of the WFA-positive L1CAM assay with the high sensitive assay detecting WFA-positive sialylated mucin 1 sufficiently improved the diagnostic accuracy of CC (overall accuracy. =. 0.84, AUC. =. 0.93). This combination will possibly be a precise procedure for CC diagnosis compared with conventional diagnostic techniques. Biological significanceIn this study, we constructed the system for verification of the candidate molecules that exhibit disease specific glyco-alterations and discovered a useful CC marker by the glycoproteomics-assisted strategy for biomarker discovery. Based on the strategy, we previously found that WFA is the best probe to detect CC-specific glycosylation and WFA-positive sialyl MUC1 as a possible biomarker candidate. While the diagnostic specificity of WFA-positive sialyl MUC1 was not superb, we proposed a new biomarker candidate WFA-positive L1CAM with high specificity in bile and serum to complement the previous one. We proved that the novel combination assay of WFA-L1CAM and WFA-sialyl MUC1 selected based on our strategy has the possibility to become a reliable serological test. This study represents application of our strategy, which can be extrapolated to discovery of marker candidates for other diseases.",
keywords = "Biomarker, Cholangiocarcinoma, Glycoprotein, L1CAM, Lectin",
author = "Atsushi Matsuda and Atsushi Kuno and Hideki Matsuzaki and Toru Kawamoto and Toshihide Shikanai and Yasuni Nakanuma and Masakazu Yamamoto and Nobuhiro Ohkohchi and Yuzuru Ikehara and Junichi Shoda and Jun Hirabayashi and Hisashi Narimatsu",
year = "2013",
month = "6",
day = "24",
doi = "10.1016/j.jprot.2013.04.017",
language = "English",
volume = "85",
pages = "1--11",
journal = "Journal of Proteomics",
issn = "1874-3919",
publisher = "Elsevier",

}

TY - JOUR

T1 - Glycoproteomics-based cancer marker discovery adopting dual enrichment with Wisteria floribunda agglutinin for high specific glyco-diagnosis of cholangiocarcinoma

AU - Matsuda, Atsushi

AU - Kuno, Atsushi

AU - Matsuzaki, Hideki

AU - Kawamoto, Toru

AU - Shikanai, Toshihide

AU - Nakanuma, Yasuni

AU - Yamamoto, Masakazu

AU - Ohkohchi, Nobuhiro

AU - Ikehara, Yuzuru

AU - Shoda, Junichi

AU - Hirabayashi, Jun

AU - Narimatsu, Hisashi

PY - 2013/6/24

Y1 - 2013/6/24

N2 - Cholangiocarcinoma (CC) is a lethal malignancy because it exhibits asymptomatic growth infiltrating the surrounding structures and therefore is usually detected at an advanced stage. The mainstay of treatment for CC is complete resection with negative surgical margins. Therefore, its diagnosis at a relatively early stage is demanded for performing relevant surgical resection. Since the definitive CC diagnosis depends on invasive methods such as biliary cytology and biopsy, a noninvasive assay with high diagnostic accuracy is keenly required. We therefore developed a CC marker with high specificity by the Wisteria floribunda agglutinin (WFA)-assisted glycoproteomics approach. WFA-positive glycoproteins were enriched by the direct dissection of the WFA-stained CC tissue region and following WFA-agarose column chromatography. Subsequent analysis by mass spectrometry identified 71 proteins as candidate markers. Screening of these candidates by gene expression profiling and immunohistochemistry resulted in the selection of L1 cell adhesion molecule (L1CAM) as the most specific CC marker. We confirmed the importance of WFA-positivity for L1CAM using both bile and serum of CC and benign bile duct disease patients. Specifically, WFA-positive L1CAM was enriched from serum by the WFA-assisted affinity capturing, with which CC was efficiently distinguished from benign. In the primary verification study using bile from CC patients (n. =. 29) and that of benign bile duct disease (n. =. 29), WFA-positive L1CAM distinguished CC with high specificity (sensitivity. =. 0.66, specificity. =. 0.93, overall accuracy. =. 0.79, area under the receiver operating curve [AUC]. =. 0.82). The combined use of the WFA-positive L1CAM assay with the high sensitive assay detecting WFA-positive sialylated mucin 1 sufficiently improved the diagnostic accuracy of CC (overall accuracy. =. 0.84, AUC. =. 0.93). This combination will possibly be a precise procedure for CC diagnosis compared with conventional diagnostic techniques. Biological significanceIn this study, we constructed the system for verification of the candidate molecules that exhibit disease specific glyco-alterations and discovered a useful CC marker by the glycoproteomics-assisted strategy for biomarker discovery. Based on the strategy, we previously found that WFA is the best probe to detect CC-specific glycosylation and WFA-positive sialyl MUC1 as a possible biomarker candidate. While the diagnostic specificity of WFA-positive sialyl MUC1 was not superb, we proposed a new biomarker candidate WFA-positive L1CAM with high specificity in bile and serum to complement the previous one. We proved that the novel combination assay of WFA-L1CAM and WFA-sialyl MUC1 selected based on our strategy has the possibility to become a reliable serological test. This study represents application of our strategy, which can be extrapolated to discovery of marker candidates for other diseases.

AB - Cholangiocarcinoma (CC) is a lethal malignancy because it exhibits asymptomatic growth infiltrating the surrounding structures and therefore is usually detected at an advanced stage. The mainstay of treatment for CC is complete resection with negative surgical margins. Therefore, its diagnosis at a relatively early stage is demanded for performing relevant surgical resection. Since the definitive CC diagnosis depends on invasive methods such as biliary cytology and biopsy, a noninvasive assay with high diagnostic accuracy is keenly required. We therefore developed a CC marker with high specificity by the Wisteria floribunda agglutinin (WFA)-assisted glycoproteomics approach. WFA-positive glycoproteins were enriched by the direct dissection of the WFA-stained CC tissue region and following WFA-agarose column chromatography. Subsequent analysis by mass spectrometry identified 71 proteins as candidate markers. Screening of these candidates by gene expression profiling and immunohistochemistry resulted in the selection of L1 cell adhesion molecule (L1CAM) as the most specific CC marker. We confirmed the importance of WFA-positivity for L1CAM using both bile and serum of CC and benign bile duct disease patients. Specifically, WFA-positive L1CAM was enriched from serum by the WFA-assisted affinity capturing, with which CC was efficiently distinguished from benign. In the primary verification study using bile from CC patients (n. =. 29) and that of benign bile duct disease (n. =. 29), WFA-positive L1CAM distinguished CC with high specificity (sensitivity. =. 0.66, specificity. =. 0.93, overall accuracy. =. 0.79, area under the receiver operating curve [AUC]. =. 0.82). The combined use of the WFA-positive L1CAM assay with the high sensitive assay detecting WFA-positive sialylated mucin 1 sufficiently improved the diagnostic accuracy of CC (overall accuracy. =. 0.84, AUC. =. 0.93). This combination will possibly be a precise procedure for CC diagnosis compared with conventional diagnostic techniques. Biological significanceIn this study, we constructed the system for verification of the candidate molecules that exhibit disease specific glyco-alterations and discovered a useful CC marker by the glycoproteomics-assisted strategy for biomarker discovery. Based on the strategy, we previously found that WFA is the best probe to detect CC-specific glycosylation and WFA-positive sialyl MUC1 as a possible biomarker candidate. While the diagnostic specificity of WFA-positive sialyl MUC1 was not superb, we proposed a new biomarker candidate WFA-positive L1CAM with high specificity in bile and serum to complement the previous one. We proved that the novel combination assay of WFA-L1CAM and WFA-sialyl MUC1 selected based on our strategy has the possibility to become a reliable serological test. This study represents application of our strategy, which can be extrapolated to discovery of marker candidates for other diseases.

KW - Biomarker

KW - Cholangiocarcinoma

KW - Glycoprotein

KW - L1CAM

KW - Lectin

UR - http://www.scopus.com/inward/record.url?scp=84877880275&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877880275&partnerID=8YFLogxK

U2 - 10.1016/j.jprot.2013.04.017

DO - 10.1016/j.jprot.2013.04.017

M3 - Article

VL - 85

SP - 1

EP - 11

JO - Journal of Proteomics

JF - Journal of Proteomics

SN - 1874-3919

ER -